Moderna
VC Fund
Cambridge, United States
Moderna is a VC fund in Cambridge focused on Biotechnology and Health Care. Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies insidepatient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Moderna invests in
Stages Moderna invests in
Countries Moderna invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 8 contacts → | |||
Investment Focus
Industry
- Biotechnology 3 (60%)
- Health Care 2 (40%)
- Genetics 1 (20%)
- Hedge Funds 1 (20%)
- Therapeutics 1 (20%)
Stage
- Series B 1 (20%)
- Debt Financing 1 (20%)
- Post-IPO Equity 1 (20%)
- Venture - Series Unknown 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Eric Ma
Principal Data Scientist
|
Principal Data Scientist | Total investments: 0 | Find email | |
Kenneth Chien
Co-Founder
|
Co-Founder | Total investments: 2 | Find email | |
Marcello Damiani
Chief Digital & Operational Excellence Officer
|
Chief Digital & Operational Excellence Officer | Total investments: 0 | Find email | |
John Mendlein
President, Corporate and Product Strategy
|
President, Corporate and Product Strategy | Total investments: 0 | Find email | |
Noubar Afeyan
Chairman & Co-Founder
|
Chairman & Co-Founder | Total investments: 34 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Generation Bio is an innovative genetic medicines company focused on creating a new class of gene therapy to provide durable, redosable treatments for patients suffering from both rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novelcell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company is designing therapies to provide targeted delivery of genetic payloads that include large and multiple genes across a broad array of tissues, and to be redosable for individualized and extended treatment throughout a patient’s life. The platform is designed to expand access to treatments for rare diseases and to address prevalent diseases through efficient, scalable manufacturing. | $76M / Post-IPO Equity / Mar 23, 2023 | ||
| Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems. | $100M / Series B / Jan 05, 2023 | ||
| Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems. | $175M / Series B / Jan 25, 2022 | ||
Leightal Capital Management
|
Leightal Capital Management is a global hedge fund that invests in a variety of asset classes, including equities, fixed income, and commodities. The fund is managed by a team of experienced professionals with a proven track record of success. Leightal Capital Management is committed to providing its investors with superior returns over the longterm. The fund's investment philosophy is based on the belief that alpha can be generated by identifying and investing in mispriced assets. The fund's investment team uses a variety of research and analysis techniques to identify mispriced assets. The team also has a strong focus on risk management and capital preservation. Leightal Capital Management is a good choice for investors who are looking for a long-term investment partner with a proven track record of success. | $5.5M / Debt Financing / Jan 01, 2022 | |
| The Onkaido Therapeutics team is exploring how messenger RNA therapeutics™ can deliver novel oncology drugs to help patients. | $20M / Venture - Series Unknown / Jan 14, 2014 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Moderna invest in?
Moderna invests primarily in Biotechnology, Health Care and Genetics startups, most often at Series B and Debt Financing stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Moderna?
Public channels for Moderna include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Moderna?
The team at Moderna includes Eric Ma (Principal Data Scientist), Kenneth Chien (Co-Founder) and Marcello Damiani (Chief Digital & Operational Excellence Officer), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
